Pulmonx highlights $12 billion global opportunity for Zephyr valves in investor presentation
LUNG•Pulmonx reported third-quarter 2026 revenue of $22.8 million, including $14.9 million in the U.S., and estimated a $12 billion global opportunity for Zephyr valves across 1.2 million eligible patients.
1. Quarterly figures
Pulmonx reported third-quarter 2026 revenue of $22.8 million, including $14.9 million in U.S. revenue. Gross margin was 76%, and cash, cash equivalents and marketable securities totaled $52.7 million as of September 30, 2026.
2. Zephyr opportunity
The investor presentation estimated a $12 billion global opportunity for Zephyr valves across 1.2 million eligible patients. Investigational AeriSeal technology could expand the addressable market by at least 20% by making currently ineligible patients eligible for Zephyr treatment.
